6 July 2011 Dr. Marta Palicio, Scientific Business Developer at Oryzon, has been invited to participate in the roundtable Biomarkers and translational medicine: new paradigms for personalized medicine
26 January 2012 Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6
6 February 2012 Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease